Abbott commences new study of Xience stent patients on antiplatelet therapy

Abbott has announced the commencement of a new study assessing the use of its Xience coronary stent among patients receiving common blood-thinning medicines.

The first patient has been enrolled in a clinical study evaluating the short-term use of dual antiplatelet therapies after receiving a Xience everolimus-eluting coronary stent, in order to evaluate the safety performance.

Researchers are aiming to determine if three months of dual antiplatelet therapy is non-inferior to the current standard of 12 months after implantation with a Xience stent for patients who are at high risk of bleeding.

The study will enroll approximately 2,000 patients at 100 sites in the US and Asia, and is intended to help usher in a new treatment option for people at higher risk of bleeding due to factors such as older age, anaemia and renal disease.

Dr Charles Simonton, chief medical officer and divisional vice-president of medical affairs for Abbott's vascular business, said: "We continue to advance Xience research with the goal of helping even more people return to their daily lives as quickly as possible."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.